24-h Efficacy of Glaucoma Treatment Options

被引:0
|
作者
Anastasios G. P. Konstas
Luciano Quaranta
Banu Bozkurt
Andreas Katsanos
Julian Garcia-Feijoo
Luca Rossetti
Tarek Shaarawy
Norbert Pfeiffer
Stefano Miglior
机构
[1] Aristotle University of Thessaloniki,1st University Department of Ophthalmology
[2] Aristotle University of Thessaloniki,3rd University Department of Ophthalmology
[3] University of Brescia,Glaucoma Unit
[4] Selcuk University,Department of Ophthalmology
[5] University of Ioannina,Department of Ophthalmology
[6] University of Madrid,Eye Clinic, San Paolo Hospital
[7] University of Milan,Glaucoma Sector
[8] University of Geneva,Department of Ophthalmology
[9] University of Mainz,undefined
[10] University Bicocca of Milan,undefined
来源
Advances in Therapy | 2016年 / 33卷
关键词
24-h efficacy; 24-h intraocular pressure control; Circadian intraocular pressure characteristics; Diurnal intraocular pressure; Glaucoma therapy options; Intraocular pressure monitoring; Ophthalmology;
D O I
暂无
中图分类号
学科分类号
摘要
Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss. In the published literature, the hypothesis is often made that IOP control implies a single IOP measurement over time. Although the follow-up of glaucoma patients with single IOP measurements is quick and convenient, such measurements often do not adequately reflect the untreated IOP characteristics, or indeed the quality of treated IOP control during the 24-h cycle. Since glaucoma is a 24-h disease and the damaging effect of elevated IOP is continuous, it is logical that we should aim to understand the efficacy of all treatment options throughout the 24-h period. This article first reviews the concept and value of diurnal and 24-h IOP monitoring. It then critically evaluates selected available evidence on the 24-h efficacy of medical, laser and surgical therapy options. During the past decade several controlled trials have significantly enhanced our understanding on the 24-h efficacy of all glaucoma therapy options. Nevertheless, more long-term evidence is needed to better evaluate the 24-h efficacy of glaucoma therapy and the precise impact of IOP characteristics on glaucomatous progression and visual prognosis.
引用
收藏
页码:481 / 517
页数:36
相关论文
共 50 条
  • [31] Comparison of Hydrus and iStent microinvasive glaucoma surgery implants in combination with phacoemulsification for treatment of open-angle glaucoma: systematic review and network meta-analysis
    Hu, Rongrong
    Guo, Dongyu
    Hong, Nan
    Xuan, Xiuyuan
    Wang, Xiaoyu
    BMJ OPEN, 2022, 12 (06):
  • [32] Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety
    Yasuaki Kuwayama
    Akio Nomura
    Advances in Therapy, 2014, 31 : 461 - 471
  • [33] Insight Into Glaucoma Treatment in the Early 1900s Harvey Cushing's 1905 Operation
    Latimer, Katherine
    Pendleton, Courtney
    Martinez, Alejandro
    Subramanian, Prem S.
    Quinones-Hinojosa, Alfredo
    ARCHIVES OF OPHTHALMOLOGY, 2012, 130 (04) : 510 - 513
  • [34] Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?
    Mouhammad, Zaynab Ahmad
    Vohra, Rupali
    Horwitz, Anna
    Thein, Anna-Sophie
    Rovelt, Jens
    Cvenkel, Barbara
    Williams, Pete A.
    Azuara-Blanco, Augusto
    Kolko, Miriam
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [35] Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety
    Kuwayama, Yasuaki
    Nomura, Akio
    ADVANCES IN THERAPY, 2014, 31 (04) : 461 - 471
  • [36] Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence
    Kuwayama, Yasuaki
    Hashimoto, Masako
    Kakegawa, Reiko
    Nomura, Akio
    Shimada, Fumiki
    ADVANCES IN THERAPY, 2017, 34 (06) : 1411 - 1425
  • [37] Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence
    Yasuaki Kuwayama
    Masako Hashimoto
    Reiko Kakegawa
    Akio Nomura
    Fumiki Shimada
    Advances in Therapy, 2017, 34 : 1411 - 1425
  • [38] Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study
    Rabiolo, Alessandro
    Montesano, Giovanni
    Crabb, David P.
    Garway-Heath, David F.
    OPHTHALMOLOGY, 2024, 131 (08) : 902 - 913
  • [39] Comparative Study of Latanoprost Drug Delivery Systems for Glaucoma Treatment and Their Interaction with the Tear Film Lipid Layer Models
    Saija, Maria Chiara
    Vazdar, Katarina
    Pajerski, Wojciech
    Olzynska, Agnieszka
    Daull, Philippe
    Garrigue, Jean-Sebastien
    Cwiklik, Lukasz
    MOLECULAR PHARMACEUTICS, 2023, 21 (01) : 126 - 136
  • [40] Safety and Efficacy of YAG Laser Vitreolysis for the Treatment of Vitreous Floaters: An Overview
    Katsanos, Andreas
    Tsaldari, Nikoleta
    Gorgoli, Konstantina
    Lalos, Fotios
    Stefaniotou, Maria
    Asproudis, Ioannis
    ADVANCES IN THERAPY, 2020, 37 (04) : 1319 - 1327